MRD and Decision-Making in Early Stage Colorectal Cancer

home / oncview / mrd-and-decision-making-in-early-stage-colorectal-cancer

Experts focus in on optimizing the use of minimal residual disease as a tool to guide decision making in the adjuvant setting for patients at risk for recurrence with colorectal cancer.

Genomic Profiling in Early CRC

EP. 1: Genomic Profiling in Early CRC

Daniel Ahn, DO;Christopher Lieu, MD;Kristie L. Kahl
March 26th 2021

Christopher Lieu, MD, discusses the standard of care for genomic profiling in early stage CRC.

Minimal Residual Disease Testing in Early CRC

EP. 2: Minimal Residual Disease Testing in Early CRC

April 26th 2021

Daniel Ahn, DO, reviews MRD as a novel approach to assessing risk for recurrence and response to treatment in early stage CRC.

Role of ctDNA in Assessing Risk for Recurrence in Early CRC

EP. 3: Role of ctDNA in Assessing Risk for Recurrence in Early CRC

Christopher Lieu, MD;Kristie L. Kahl
May 21st 2021

A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.

Assessing Risk for Recurrence in Early CRC

EP. 4: Assessing Risk for Recurrence in Early CRC

Daniel Ahn, DO;Kristie L. Kahl
June 25th 2021

Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.

Personalized MRD Testing in Early CRC

EP. 5: Personalized MRD Testing in Early CRC

Christopher Lieu, MD;Kristie L. Kahl
July 23rd 2021

An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.

Unmet Needs and Open Questions in Early CRC

EP. 6: Unmet Needs and Open Questions in Early CRC

Christopher Lieu, MD;Kristie L. Kahl
August 20th 2021

Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.

MRD and Decision-Making in Early-Stage Colorectal Cancer

EP. 7: MRD and Decision-Making in Early-Stage Colorectal Cancer

Christopher Lieu, MD;Daniel Ahn, DO
August 20th 2021

This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.